Ferulic acid ameliorates hyperuricemia by regulating xanthine oxidase

Int J Biol Macromol. 2023 Dec 31;253(Pt 3):126542. doi: 10.1016/j.ijbiomac.2023.126542. Epub 2023 Aug 26.

Abstract

Hyperuricemia is characterized by elevated uric acid (UA) level in the body. The xanthine oxidase (XO) inhibitory ability is an important way to evaluate the anti-hyperuricemia effect of natural products. Ferulic acid (FA) is a phenolic acid compound, and it is a free radical scavenger with many physiological functions. The aim of this study was to investigate the structure-activity relationship, potential mechanism and interaction of FA as XO's inhibitor. In the cell experiment, using 1.25 mM adenosine to incubate for 24 h under the optimal conditions (37 °C, pH = 7.2) can increase the UA production by 1.34 folds. PCR analysis showed that FA could reduce the mRNA expression level of XO. FA inhibited XO in a mixed mode (IC50 = 13.25 μM). The fluorescence quenching of XO by FA occurs through a static mechanism, with an inhibition constant of Ki = 9.527 × 10-5 mol L-1 and an apparent coefficient of α = 1.768. The enthalpy and entropy changes were found as -267.79 KJ mol-1 and - 860.85 KJ mol-1, indicating that both hydrogen binding and hydrophobic are involved in the interaction of this polyphenolic natural compound with XO. Thus, FA supplementation may be a potential therapeutic strategy to improve hyperuricemia by reducing UA production.

Keywords: Ferulic acid; Hyperuricemia; Xanthine oxidase.

MeSH terms

  • Coumaric Acids / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hyperuricemia* / drug therapy
  • Structure-Activity Relationship
  • Xanthine Oxidase*

Substances

  • Xanthine Oxidase
  • ferulic acid
  • Coumaric Acids
  • Enzyme Inhibitors